Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

36.57 +0.01 (+0.03%)
Streaming Delayed Price Updated: 11:13 AM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
37 38 Next >
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr
Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Exposures Product Safety
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK). 
Via InvestorPlace
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..
Reuters 
Via Benzinga
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
Via Benzinga
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
Via Benzinga
GSK's Rare Blood Cancer Candidate Goes Under FDA Review
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement. 
Via InvestorPlace
Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic
GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr.  
Via Benzinga
Jim Cramer Says This Stock Is A 'Great Spec And I Usually Don't Say That,' And Analysts Approve
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Certara, Inc. (NASDAQ: CERT) is not bad and also not losing money. "I think it’s a great spec, and I usually don’t say that," he added. 
Via Benzinga
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
One Suit Down Out Of 3,000 Zantac Related Lawsuits, Says GSK
Via Benzinga
Why IDEAYA Biosciences Shares Plunging Today
Via Benzinga
Haleon Clocks Double Digit Growth In Interim Revenue, Profits; Sticks To Annual Guidance
Via Benzinga
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
Via Benzinga
Recent Stock Purchase September 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. 
Via Talk Markets
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
Pfizer's Pentavalent Meningococcal Vaccine Candidate Shows Efficacy In Adolescents
Via Benzinga
September 2022 Stock Considerations
Let’s take a look at my September stock considerations which are similar to recent considerations from one to four months ago. 
Via Talk Markets
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Novartis Appoints Merck Executive As Research Head
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
IDEAYA Achieves First Milestone In GSK Pact For Pol Theta Helicase Inhibitor Candidate
Via Benzinga
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
Via Benzinga
Recent Stock Purchase August 2022
I just continue to have a long-term outlook, continue to invest, diversify my portfolio even more and just hold on. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
Sanofi's Run Of Bad Luck Continues As Pharma Giant Tosses Out A Cancer Drug
Shares extended deep losses following a Zantac-inspired downturn last week. 
Via Investor's Business Daily
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.